The Clinical and Laboratory Standards Institute Announces the Publication of New Antimicrobial Susceptibility Testing Documents CLSI M100-Ed34, M02-Ed14, and M07-Ed12

Malvern, Pennsylvania, USA—The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition.

The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures defined in CLSI standards CLSI M02, M07, and M11, which cover the most up-to-date recommended methods for susceptibility testing and quality control. CLSI M100 is an essential companion to these standards and is a valuable tool for microbiology labs, antimicrobial stewardship teams, infectious disease experts, and other health care professionals. Users should replace previously published tables with the new edition to ensure accurate testing and patient safety.

“The annual update of M100 is key to ensuring that labs are providing their clinicians and stewardship teams with the most up-to-date susceptibility criteria for patient care,” said James S. Lewis II, PharmD, FIDSA, chairholder of the Subcommittee on Antimicrobial Susceptibility Testing (AST).

"The annual revision of M100 ensures that new data and new antimicrobial agents are made available to laboratorians and other end users,” Jen Adams, vice-president of Standards and Quality at CLSI, said. “By using the most updated information available, it allows laboratorians and clinicians to optimize patient care."

With the new document updates this year, CLSI is offering its customers the following package pricing:
CLSI M02 + CLSI M100 Package in Print
CLSI M02 + CLSI M100 Package in Electronic Format (PDF)

CLSI M07 + CLSI M100 Package in Print
CLSI M07 + CLSI M100 Package in Electronic Format (PDF)

CLSI M100 + CLSI M02 + CLSI M07 Package in Print
CLSI M100 + CLSI M02 + CLSI M07 Package in Electronic Format (PDF)

In addition, CLSI will host its annual What’s New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing webinar hosted by Janet Hindler, MCLS, MT(ASCP), F(AAM), of the Los Angeles Department of Public Health. The webinar will include laboratory experts Romney M. Humphries, PhD, D(ABMM) of Vanderbilt University and April M. Bobenchik, PhD, D(ABMM), MT(ASCP), of Penn State Health and Milton S. Hershey Medical Center.

The webinar is designed to help users identify the major changes in the new editions, learn implementation strategies, and suggest communication approaches for informing clinical staff about the significant AST and reporting changes. Some of the major updates that will be discussed during the webinar include:

• A significant reorganization of dosage recommendations.
• The addition of sulbactam-durlobactam to breakpoints.
• A new Table 2A-2 for Salmonella and Shigella.

Substantive changes to CLSI M02 and CLSI M07 will also be discussed. The webinar will take place on 17 April 2024 from 1:00-2:30 PM ET.

For more information, contact Jane Berger at jberger@clsi.org or +1.484.588.5936.

CLSI is the leading global non-profit laboratory medicine standards development organization, with over 24,000 professional members, 2,000 active volunteers, and 250 standards products. CLSI standards are recognized by laboratories, accreditors, and government agencies worldwide as the best way to improve their testing outcomes, maintain accreditation, bring products to market faster, and navigate regulatory hurdles.